PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy

Author(s):
Luk, S.J.; Steen, D.M. van der; Hagedoorn, R.S.; Jordanova, E.S.; Schilham, M.W. (0000-0003-4391-6003); Bovee, J.V.M.G. (0000-0003-1155-0481); Cleven, A.H.G.; Falkenburg, J.H.F.; Szuhai, K. (0000-0002-1228-4245); Heemskerk, M.H.M. (0000-0001-6320-9133)
Published
2018
Publication type
Article / Letter to editor
Synovial sarcomaHLA Class IPRAMET-cell infiltrationTCR-gene therapy
Date issued
2018-12-02
Language
English
Is part of
OncoImmunology (2018), No. 12
hdl
1887/75940
doi
10.1080/2162402X.2018.1507600